ELS-tíðindi - október 2002 - Einkaleyfastofan

10/02
(21) 6561
(22) 20.9.2002
(41) 20.9.2002
(51) C07D 401/00
(54) Bensóamíð píperidín efnasambönd
sem P-efnis mótlyf.
(71) Pfizer Products Inc., Eastern Point
Road, Groton, Connecticut 06340,
Bandaríkjunum.
(72) Eric Platt Arnold; Thomas Allen
Chappie; Jianhua Huang; John
Michael Humphrey; Arthur Adam
Nagel; Brian Thomas O'Neill; Susan
Beth Sobolov-Jaynes; Lawrence
Albert Vincent; Groton, Connecticut,
Bandaríkjunum.
(74) Faktor einkaleyfaskrifstofa, ehf.,
Pósthólf 678, 121 Reykjavík.
(30) 10.4.2000, US, 60/195,922
20.6.2000, US, 60/212,922
(85) 20.9.2002
(86) 6.4.2001, PCT/IB01/00629
(21) 6562
(22) 23.9.2002
(41) 23.9.2002
(51) B65D 79/02; G01K 11/06
(54) Umbúðir, ásamt til þess gerðum
hitamæli, til að geyma til varðveislu
vörur við lækkað hitastig.
(71) Henry Norrby; Mats Nygårdh;
Öjevägen 69, S-820 40 Järvsö; Myra
2289 A, S-820 40 Järvsö, Svíþjóð.
(72) Henry Norrby; Mats Nygårdh; Järvsö,
Svíþjóð.
(74) Kjartan Ragnars, hrl., Hrauntungu
66, 200 Kópavogi.
(30) 27.3.2000, SE, 0001069-4
(85) 23.9.2002
(86) 26.3.2001, PCT/SE01/00650
(21) 6563
(22) 24.9.2002
(41) 24.9.2002
(51) C07D 401/06; C07D 403/06; C07D
405/06; C07D 409/06; C07D 295/155;
A61K 31/4523; A61P 25/04; A61P
25/00
(54) Hýdroxýfenýl-píperasinýl-metýlbensamíðafleiður
til að meðhöndla
sársauka.
(71) AstraZeneca AB, S-151 85 Södertälje,
Svíþjóð.
(72) William Brown; Niklas Plobeck;
Christopher Walpole; St. Laurent,
Quebec, Kanada.
(74) Sigurjónsson & Thor, ehf.,
Skólavörðustíg 16, 101 Reykjavík.
(30) 4.4.2000, SE, 0001209-6
(85) 24.9.2002
(86) 30.3.2001, PCT/SE01/00709
(21) 6564
(22) 24.9.2002
(41) 24.9.2002
(51) A61M 5/30
(54) Nálarlaus sprauta sem verkar með
leifturhleðslu með tvöfaldri samsetningu.
(71) Crossject, 12, Quai Henri IV, 75181
Paris Cedex 04, Frakklandi.
ELS tíðindi 57
(72) Patrick Alexandre, Gray; Patrick
Cognot, Le Mee Sur Seine; Joël
Lafforgue, Itteville; Denis Roller, La
Ferte Alais; Frakklandi.
(74) Faktor einkaleyfaskrifstofa, ehf.,
Pósthólf 678, 121 Reykjavík.
(30) 19.4.2000, FR, 00/05,031
(85) 24.9.2002
(86) 27.3.2001, PCT/FR01/00921
(21) 6565
(22) 24.9.2002
(41) 24.9.2002
(51) C07D 451/00
(54) Trópan afleiður nytsamlegar í
meðferð.
(71) Pfizer Inc., 235 East 42nd Street,
New York, New York 10017,
Bandaríkjunum.
(72) Manoussos Perros; David Anthony
Price; Blanda Luzia Christa Stammen;
Anthony Wood; Sandwich, Kent,
Bretlandi.
(74) Faktor einkaleyfaskrifstofa, ehf.,
Pósthólf 678, 121 Reykjavík.
(30) 26.5.2000, GB, 0014046.7
27.6.2000, GB, 0015835.2
(85) 24.9.2002
(86) 9.5.2001, PCT/IB01/00806
(21) 6566
(22) 24.9.2002
(41) 24.9.2002
(51) C07D 209/34; A61K 31/404; A61P
5/10; C07D 209/38; C07D 405/10;
C07D 401/04; C07D 401/12; C07D
403/12; C07D 403/10; C07D 401/10;
C07D 405/12
(54) Indólín-2-ón afleiður, framleiðsla og
notkun þeirra sem mjaltavaka
(ocytocin) viðtakabindlar.
(71) Sanofi-Synthelabo, 174 Avenue de
France, FR-75013 Paris, Frakklandi.
(72) Loïc Foulon, Portet sur Garonne;
Georges Garcia, Frontignan;
Claudine Serradeil-Le Gal,
Esclaquens; Gérard Valette, Lacroix-
Falgarde; Frakklandi.
(74) Faktor einkaleyfaskrifstofa, ehf.,
Pósthólf 678, 121 Reykjavík.
(30) 3.4.2000, FR, 00/04,193
(85) 24.9.2002
(86) 2.4.2001, PCT/FR01/00980
(21) 6567
(22) 24.9.2002
(41) 24.9.2002
(51) C07D 401/04; A61K 31/415
(54) Natríum-vetnis skiptilati af gerð 1
(NHE-1).
(71) Pfizer Products Inc., Eastern Point
Road, Groton, Connecticut 06340,
Bandaríkjunum.
(72) Weichao George Chen; Eric David
Cox; Angel Guzman-Perez; Groton,
Connecticut, Bandaríkjunum.
(74) Faktor einkaleyfaskrifstofa, ehf.,
Pósthólf 678, 121 Reykjavík.
(30) 28.4.2000, US, 60/200,432
(85) 24.9.2002
(86) 28.2.2001, PCT/IB01/00277
(21) 6568
(22) 26.9.2002
(41) 26.9.2002
(51) C01B 3/38; H01M 8/6
(54) Fjölþrepa brennsla fyrir eldsneytisvinnslu
til að nota með efnarafal.
(71) UOP LLC, 25 Eest Algonquin Road,
Des Plaines, Illinois 60017-5017,
Bandaríkjunum.
(72) John Joseph Senetar; Gavin P.
Towler; John Robert Harness; Des
Plaines, Illinois, Bandaríkjunum.
(74) Sigurjónsson & Thor, ehf.,
Skólavörðustíg 16, 101 Reykjavík.
(30) 29.3.2000, US, 09/538,424
(85) 26.9.2002
(86) 28.3.2001, PCT/US01/10007
(21) 6569
(22) 27.9.2002
(41) 27.9.2002
(51) C07C 215/54; C07C 217/60; C07C
215/56; C07C 217/16; C07C 271/24;
C07C 233/23; C07C 323/25; C07D
213/38; A61K 31/137; A61K 31/4402;
A61K 31/4406; A61K 31/4409; A61K
31/27; A61K 31/165; A61P 25/16
(54) Sýklóhexýlamín afleiða sem valvís
NMDA viðtakamótlyf af undirgerð.
(71) Warner-Lambert Company, 201
Tabor Road, Morris Plains, New
Jersey 07950, Bandaríkjunum.
(72) Russell Joseph Deorazio,
Schenectady, New York; Sham
Shridhar Nikam, Ann Arbor,
Michigan; Ian Leslie Scott, Delanson,
New York; Brian Alan Sherer, Clifton
Park, New York; Lawrence David
Wise, Ann Arbor, Michigan;
Bandaríkjunum.
(74) Faktor einkaleyfaskrifstofa, ehf.,
Pósthólf 678, 121 Reykjavík.
(30) 26.4.2000, US, 60/199,762
(85) 27.9.2002
(86) 24.4.2001, PCT/US01/13176
(21) 6570
(22) 27.9.2002
(41) 27.9.2002
(51) A61K 31/00
(54) Þrýstingslækkandi miðlar og notkun.
(71) Warner-Lambert Company, 201
Tabor Road, Morris Plains, New
Jersey 07950, Bandaríkjunum.
(72) Karen Diane Hitchcock, Pequannock,
New Jersey; Bruce Jeffrey Auerbach,
Ann Arbor, Michigan; Michael John
Ryan, Ann Arbor, Michigan;
Bandaríkjunum.
(74) Faktor einkaleyfaskrifstofa, ehf.,
Pósthólf 678, 121 Reykjavík.
(30) 20.10.2000, US, 60/242,280
26.4.2000, US, 60/199,855
(85) 27.9.2002
(86) 22.3.2001, PCT/US01/09088